- Home
- LFT vs SERA Comparison
LFT vs SERA Comparison
Compare LFT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | SERA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 75.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFT | SERA |
|---|---|---|
| Price | $1.14 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.5K | 23.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $668.15 | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $1.12 | $1.37 |
| 52 Week High | $2.65 | $4.09 |
Technical Indicators
Market Signals| Indicator | LFT | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 30.83 | 34.37 |
| Support Level | N/A | N/A |
| Resistance Level | $1.40 | $2.41 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 11.11 | 13.28 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.